Patents by Inventor Peter Zerhouni

Peter Zerhouni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEW THERAPY
    Publication number: 20240043847
    Abstract: The present invention provides an oligonucleotide comprising the sequence 5?-GGAACAGTTCGTCCATGGC-3? (SEQ ID NO:2) for use in the treatment of inflammatory bowel disease in a human subject, wherein individual doses of from 100 mg to 350 mg of said oligonucleotide are administered to the subject on at least four separate occasions, wherein the separate occasions are each a week apart.
    Type: Application
    Filed: September 14, 2023
    Publication date: February 8, 2024
    Inventors: Arezou Zargari, Charlotte Admyre, Pernilla Sandwall, Thomas Knittel, Peter Zerhouni
  • Therapy
    Patent number: 11795462
    Abstract: The present invention provides an oligonucleotide comprising the sequence 5?-GGAACAGTTCGTCCATGGC-3? (SEQ ID NO:2) for use in the treatment of inflammatory bowel disease in a human subject, wherein individual doses of from 100 mg to 350 mg of said oligonucleotide are administered to the subject on at least four separate occasions, wherein the separate occasions are each a week apart.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: October 24, 2023
    Assignee: Index Pharmaceuticals AB
    Inventors: Arezou Zargari, Charlotte Admyre, Pernilla Sandwall, Thomas Knittel, Peter Zerhouni
  • FORMULATION
    Publication number: 20230181480
    Abstract: The present invention relates a formulation and capsule suitable for oral administration. The invention further relates to the use of the formulation and capsule for treating inflammatory bowel diseases, for instance ulcerative colitis (UC) or Crohn's disease.
    Type: Application
    Filed: January 6, 2023
    Publication date: June 15, 2023
    Inventors: Paul Alhadeff, Christine Dieterich Johansson, Peter Zerhouni, Wei Tian, Graeme William Andrew Hamilton Johnston
  • Formulation
    Patent number: 11596608
    Abstract: The present invention relates a formulation and capsule suitable for oral administration. The invention further relates to the use of the formulation and capsule for treating inflammatory bowel diseases, for instance ulcerative colitis (UC) or Crohn's disease.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: March 7, 2023
    Assignee: Index Pharmaceuticals AB
    Inventors: Paul Alhadeff, Christine Dieterich Johansson, Peter Zerhouni, Wei Tian, Graeme William Andrew Hamilton Johnston
  • OLIGONUCLEOTIDE-BASED THERAPY FOR ULCERATIVE COLITIS
    Publication number: 20220378818
    Abstract: The present invention provides an oligonucleotide comprising the sequence 5?-GGAACAGTTCGTCCATGGC-3? (SEQ ID NO:2) for use in the treatment of an inflammatory bowel disease in a human subject via topical administration to the colon, wherein the subject has not been subjected to colonic cleaning prior to said administration.
    Type: Application
    Filed: August 21, 2020
    Publication date: December 1, 2022
    Inventors: Peter Zerhouni, Pernilla Sandwall, Thomas Knittel
  • NEW THERAPY
    Publication number: 20220218736
    Abstract: The present invention provides an oligonucleotide for use in preventing the recurrence of active ulcerative colitis in a patient, wherein the oligonucleotide comprises the sequence 5?-GGAACAGTTCGTCCATGGC-3? (SEQ ID NO:2).
    Type: Application
    Filed: November 14, 2019
    Publication date: July 14, 2022
    Inventors: Arezou Zargari, Pernilla Sandwall, Charlotte Admyre, Thomas Knittel, Peter Zerhouni
  • Cobitolimod for use in the treatment of inflammatory bowel disease
    Patent number: 11166975
    Abstract: The present invention provides an oligonucleotide comprising the sequence 5?-GGAACAGTTCGTCCATGGC-3? (SEQ ID NO:2) for use in the treatment of inflammatory bowel disease in a human subject, wherein individual doses of from 150 mg to 350 mg of said oligonucleotide are administered to the subject on at least two separate occasions, wherein said separate occasions are 3 weeks apart.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: November 9, 2021
    Assignee: Index Pharmaceuticals AB
    Inventors: Arezou Zargari, Charlotte Admyre, Pernilla Sandwall, Thomas Knittel, Peter Zerhouni
  • FORMULATION
    Publication number: 20210338592
    Abstract: The present invention relates a formulation and capsule suitable for oral administration. The invention further relates to the use of the formulation and capsule for treating inflammatory bowel diseases, for instance ulcerative colitis (UC) or Crohn's disease.
    Type: Application
    Filed: May 3, 2019
    Publication date: November 4, 2021
    Inventors: Paul Alhadeff, Christine Dieterich Johansson, Peter Zerhouni, Wei Tian, Graeme William Andrew Hamilton Johnston
  • COBITOLIMOD FOR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Publication number: 20200289543
    Abstract: The present invention provides an oligonucleotide comprising the sequence 5?-GGAACAGTTCGTCCATGGC-3? (SEQ ID NO:2) for use in the treatment of inflammatory bowel disease in a human subject, wherein individual doses of from 150mg to 350 mg of said oligonucleotide are administered to the subject on at least two separate occasions, wherein said separate occasions are 3 weeks apart.
    Type: Application
    Filed: May 9, 2018
    Publication date: September 17, 2020
    Inventors: Arezou Zargari, Charlotte Admyre, Pernilla Sandwall, Thomas Knittel, Peter Zerhouni
  • NEW THERAPY
    Publication number: 20200239893
    Abstract: The present invention provides an oligonucleotide comprising the sequence 5?-GGAACAGTTCGTCCATGGC-3? (SEQ ID NO:2) for use in the treatment of inflammatory bowel disease in a human subject, wherein individual doses of from 100 mg to 350 mg of said oligonucleotide are administered to the subject on at least four separate occasions, wherein the separate occasions are each a week apart.
    Type: Application
    Filed: May 9, 2018
    Publication date: July 30, 2020
    Inventors: Arezou Zargari, Charlotte Admyre, Pernilla Sandwall, Thomas Knittel, Peter Zerhouni